SynAct Pharma CEO Acquires 20,313 Shares
CEO Jeppe Øvlesen acquired 20,313 SynAct Pharma shares on Nasdaq Stockholm. The release gives no transaction value.
CEO Jeppe Øvlesen acquired 20,313 SynAct Pharma shares on Nasdaq Stockholm. The release provides no transaction value or prior-period comparison.Material DetailsContext by AI AnalystThis is an insider purchase disclosure at a clinical-stage biotechnology company, rather than a new operating or clin…